Grifols (GRFS) Stock Price, News & Analysis

Company Overview

Grifols, Inc. (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units. The Bioscience division processes plasma to produce therapies such as immunoglobulins, albumin and coagulation factors. Its Diagnostic unit offers blood typing reagents, molecular diagnostic systems and pathogen detection technologies designed to enhance blood safety and screening. The Hospital group provides parenteral nutrition, intravenous solutions and medical devices used in surgical and critical care settings. Together, these segments support hospitals, blood banks and healthcare providers around the world.

Founded in Barcelona in 1940 by Dr. José Antonio Grífols Roig, Grifols began as a small laboratory before evolving into one of the largest plasma collection and fractionation companies worldwide. It expanded its global footprint through strategic acquisitions, including plasma collection networks in North America and Europe, and the acquisition of Talecris Biotherapeutics in 2011. The company has been publicly traded on the NASDAQ since 2006, underscoring its commitment to transparency and growth in international markets.

Headquartered in Barcelona, Spain, Grifols maintains a presence in more than 100 countries through an extensive network of donation centers, manufacturing plants and research facilities. Under the leadership of Chief Executive Officer Raimon Grifols Roura, the company continues to invest in research and development, with ongoing clinical programs aimed at advancing novel therapies and diagnostic solutions. Grifols remains dedicated to improving patient outcomes and addressing global healthcare challenges through innovation in plasma-based medicine.

Key Stats

• Today's Range: $7.46 to $7.69
• 50-Day Range: $7.32 to $8.75
• 52-Week Range: $7.26 to $11.14
• Volume: 480,284 shs
• Average Volume: 592,857 shs
• Market Capitalization: $5.20 billion
• P/E Ratio: 40.21
• Dividend Yield: 1.83%
• Price Target: $10.00
• Consensus Rating: Reduce

Grifols Stock Analysis - MarketRank™

Grifols scored higher than 92% of companies evaluated by MarketBeat, and ranked 41st out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Reduce

Consensus Rating

Grifols has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Grifols has a consensus price target of $10.00, representing about 30.9% upside from its current price of $7.64.

Amount of Analyst Coverage

Grifols has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 26.42%

Earnings Growth

Earnings for Grifols are expected to grow by 26.42% in the coming year, from $1.06 to $1.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Grifols is 40.21, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Grifols is 40.21, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.85.

Price to Earnings Growth Ratio

Grifols has a PEG Ratio of 0.28. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Grifols has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.87% of the float of Grifols has been sold short.

Short Interest Ratio / Days to Cover

Grifols has a short interest ratio ("days to cover") of 9.83.

Change versus previous month

Short interest in Grifols has recently decreased by 1.34%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Grifols pays a meaningful dividend of 1.95%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Grifols does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Grifols is 73.68%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Grifols will have a dividend payout ratio of 10.45% next year. This indicates that Grifols will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Grifols has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Grifols this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Grifols insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.19% of the stock of Grifols is held by insiders.

Percentage Held by Institutions

Grifols has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/14/2026
• Today: 6/12/2026
• Next Earnings (Estimated): 7/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRFS
• CIK: 1438569
• Web: www.grifols.com
• Phone: (493) 571-0221
• Fax: 34-93-571-0267
• Employees: 25,247
• Year Founded: 1909

Price Target and Rating

• Average Price Target for Grifols: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +30.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.19
• Trailing P/E Ratio: 40.21
• Forward P/E Ratio: 7.21
• P/E Growth: 0.29
• Net Income: $454.82 million
• Net Margins: 5.54%
• Pretax Margin: 8.18%
• Return on Equity: 6.21%
• Return on Assets: 2.39%

Debt

• Debt-to-Equity Ratio: 1.16
• Current Ratio: 2.47
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $8.51 billion
• Price / Sales: 0.61
• Cash Flow: $1.44 per share
• Price / Cash Flow: 5.29
• Book Value: $12.64 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 680,580,000
• Free Float: 679,282,000
• Market Cap: $5.20 billion
• Optionable: Optionable
• Beta: 0.65